IP Library Patent Application 10519128
Patent Application
App. No. 10/519,128

Methods and compositions for correction of cardiac conduction disturbances

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/519,128
Abstract

The invention provides methods for establishing electrical coupling between cardionyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, eg., Connexin protein such as Connexin 43 (CX43) protein, n invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac issue and for treatment of cardiac disease by transplantation into cardiac tissue.

Claims (24)

1 . A method of establishing an electrical connection-between a recombinant mammalian cell and a myocardial cell, the method comprising:

contacting a myocardial cell with a recombinant fibroblast cell genetically modified to produce a connexin protein, said contacting being in a manner sufficient to provide for production of an electrical connection between the myocardial cell and the recombinant cell;

wherein an electrical connection between the recombinant cell and the myocardial cell is established.

2 - 5 . (canceled)

6 . The method of claim 1 , wherein the connexin protein is a connexin 43 protein.

7 . The method of claim 1 , wherein said contacting comprises implanting the recombinant cell into myocardial tissue of a subject.

8 . The method of claim 1 , wherein after the electrical connection between the recombinant cell and the myocardial cell is established, the recombinant cell exhibits conductive characteristics similar to that of the myocardial cell.

9 - 12 . (canceled)

13 . A method of establishing an electrical connection between a recombinant fibroblast cell and a myocardial cell, the method comprising:

contacting a myocardial cell with a recombinant fibroblast cell genetically modified to express a recombinant connexin 43 protein, said contacting being in a inner sufficient to provide for production of an electrical connection between the myocardial cell and the recombinant fibroblast cell;

wherein an electrical connection between the recombinant fibroblast cell and the myocardial cell is established so that the recombinant fibroblast cell has conductive characteristics of the myocardial cell.

14 . A method for treating a cardiac conduction disturbance in a host, the method comprising:

introducing into cardiac tissue of a host a therapeutically effective amount of a recombinant fibroblast cell, which recombinant cell is genetically modified to express a connexin protein, said introducing being effective to establish an electrical connection between the recombinant cell and a myocardial cell of the host cardiac tissue;

wherein the cardiac conduction disturbance in the host is treated.

15 - 18 . (canceled)

19 . The method of claim 14 , wherein the connexin protein is a connexin 43 protein.

20 . The method of claim 14 , wherein said introducing comprises implanting the recombinant cell into an infarct region of the cardiac tissue.

21 . The method of claim 14 , wherein the recombinant cell is autologous to the host.

22 . A method for treating a cardiac conduction disturbance in a mammalian host, the method comprising:

introducing into cardiac tissue of the host a therapeutically effective amount of a recombinant fibroblast cell genetically modified to express a connexin 43 protein, said introducing being effective to establish an electrical connection between the introduced recombinant fibroblast cell and a myocardial cell of the host cardiac tissue;

wherein the cardiac conduction disturbance is treated.

23 - 24 . (canceled)

25 . The method of claim 22 , wherein said introducing comprises implanting the recombinant cell into an infarct region of the cardiac tissue.

26 . The method of claim 22 , wherein the recombinant fibroblast cell is autologous to the host.

Assignments (5)
SECURITY AGREEMENT Recorded Oct 19, 2009
From: CARDIOPOLYMERS, INC.
To: COMERICA BANK
Reel/Frame 023390/0110 →
CONFIRMATORY LICENSE Recorded Jun 23, 2008
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021133/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2007
From: SYMPHONY MEDICAL, INC.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 019739/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2005
From: MACIEJEWSKI, MARK
To: SYMPHONY MEDICAL, INC.
Reel/Frame 016903/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2005
From: LEE, RANDALL J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 016903/0116 →